Global Afatinib Dimaleate Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Afatinib Dimaleate Market Research Report 2024
Afatinib dimaleate is an oral molecular targeted drug developed and produced by Boehringer Ingelheim, Germany. It is a TKIs with strong and irreversible dual inhibitory effect on EGFR and HER2, and was approved by THE US FDA in July 2013.It is not only suitable for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion mutation or exon 21 (L858R) replacement mutation, but also a second - and third-line target drug for egFR-TKIS resistance.
According to Mr Accuracy reports’s new survey, global Afatinib Dimaleate market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Afatinib Dimaleate market research.
Clinical studies have shown that afatinib dimaleate reduces the risk of both cancer progression and death by 19% compared with first-generation EGFR TKI erlotinib, and significantly improves disease control rates, quality of life, and control of cancer symptoms.Prior to the Approval in China, afatinib has been approved in more than 70 countries for the treatment of PATIENTS with EGFR mutation-positive non-small cell lung cancer, and has become the preferred egFR-targeting drug in many countries.In addition, the drug was approved in 2016 by the US FDA and the European Union respectively for patients with advanced lung squamous cell carcinoma whose disease worsens during or after platinum-based chemotherapy.At present, the drug has been included in the medical insurance in China, and it can be expected that the market size of this product will gradually expand in the future.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Afatinib Dimaleate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Boehringer Ingelheim Pharmaceuticals
APExBIO Technology LLC
Carbosynth Ltd
Biorbyt
Cayman Chemical Company
Target Molecule Corp.
Frontier Specialty Chemicals
Combi-Blocks
Selleck Chemicals
AvaChem Scientific
Advanced ChemBlocks Inc
Glpbio
Nanjing Xize Pharmaceutical Technology Co., Ltd
Shandong Haiwo Biotechnology Co., Ltd
J&K Scientific
Shanghai McLin Biochemical Technology Co., Ltd
Beijing Sjar Technology Development Co., Ltd.
Beijing Wokai Biotechnology Co., Ltd
Ningbo Zhenlei Chemical Co., Ltd.
Beijing Mreda Technology Co., Ltd
MedBio Pharmaceutical Technology Inc
Shanghai Dibai Biotechnology Co., Ltd
Segment by Type
20 mg
30 mg
40 mg
Treatment of EGFR Mutated Non-Small Cell Lung Cancer
Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Afatinib Dimaleate report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Afatinib Dimaleate market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Afatinib Dimaleate market research.
Clinical studies have shown that afatinib dimaleate reduces the risk of both cancer progression and death by 19% compared with first-generation EGFR TKI erlotinib, and significantly improves disease control rates, quality of life, and control of cancer symptoms.Prior to the Approval in China, afatinib has been approved in more than 70 countries for the treatment of PATIENTS with EGFR mutation-positive non-small cell lung cancer, and has become the preferred egFR-targeting drug in many countries.In addition, the drug was approved in 2016 by the US FDA and the European Union respectively for patients with advanced lung squamous cell carcinoma whose disease worsens during or after platinum-based chemotherapy.At present, the drug has been included in the medical insurance in China, and it can be expected that the market size of this product will gradually expand in the future.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Afatinib Dimaleate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Boehringer Ingelheim Pharmaceuticals
APExBIO Technology LLC
Carbosynth Ltd
Biorbyt
Cayman Chemical Company
Target Molecule Corp.
Frontier Specialty Chemicals
Combi-Blocks
Selleck Chemicals
AvaChem Scientific
Advanced ChemBlocks Inc
Glpbio
Nanjing Xize Pharmaceutical Technology Co., Ltd
Shandong Haiwo Biotechnology Co., Ltd
J&K Scientific
Shanghai McLin Biochemical Technology Co., Ltd
Beijing Sjar Technology Development Co., Ltd.
Beijing Wokai Biotechnology Co., Ltd
Ningbo Zhenlei Chemical Co., Ltd.
Beijing Mreda Technology Co., Ltd
MedBio Pharmaceutical Technology Inc
Shanghai Dibai Biotechnology Co., Ltd
Segment by Type
20 mg
30 mg
40 mg
Segment by Application
Treatment of EGFR Mutated Non-Small Cell Lung Cancer
Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Afatinib Dimaleate report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices